How Clovis Oncology Is Positioned in November

How Clovis Oncology Is Positioned in November

Clovis Oncology (CLVS) is focused on bringing to market innovative anticancer agents. One of its products, Rubraca, has been approved for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. In July, Clovis received EMA (European Medicines Agency) approval for its application for a variation to its marketing authorization of Rubraca.